MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why LMAT Stock surged +2.90% Today — RQD Quant Desk Flash
$85.27 +2.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $85.92
LeMaitre Vascular Inc. (LMAT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (72% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $1.95B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $85.92 (+0.76%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 32.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LMAT)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (74/100 Composite)
🔍 WHY LMAT SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 32.6% FCF Margin ($81.3M FCF) & 71.5% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)
Altman Z-Score 7.30 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$80.69+0.2% Next Q
66
Q2 (-2Q)Grade B-$80.82+4.5% Next Q
69
Q3 (-1Q)Grade B$84.45+1% Next Q
71
CurrentGrade B$85.27+7.3% Hist 90D α
74
Trajectory: B- (66) → B (74)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the LMAT Bull Thesis Could Fail
Even with a 74/100 (B) score, LMAT faces multiple-compression risk if 33.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 69.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($81.20) or 200D SMA ($94.47) invalidates the momentum regime and cuts Target Base ($91.41) toward Bear Floor ($69.92).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LMAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LMAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LMAT Stock surged +2.90% Today — RQD Quant Desk Flash
LeMaitre Vascular Inc. (LMAT) surged +2.90% to $85.27, trading at 18% of its 52-week range ($78.22 – $118.01). High-quality cash engine (72% profit margin, 15% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 18% of its 52-week range ($78.22 – $118.01) with RSI-14 at 45.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.1% around $85.27 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 71.5% gross margin and $81.3M annual free cash flow.
Live LMAT Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (LMAT Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LMAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.31%⚡ TESTING RESISTANCE
2026-10-30O $85.53H $85.53L $80.03C $85.27VOL 427.4K
RES: $86.11SUP: $78.19SMA50: $81.20SMA200: $94.47
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LMAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
26.1%/yr Implied 5Y Growth
vs. +13.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LMAT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LMAT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LMAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LMAT)
Health Care Rank #54 of 1016
⚔️ XRAY vs LMAT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LMAT vs. XRAY, INSP, KMTS, ATEC)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, LeMaitre Vascular Inc. (LMAT) ranks #54 by composite RQD confidence (74/100, grade B) and #268 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LMAT
ACTIVE
LeMaitre Vascular Inc. | B | 74/100 | 33.8x | 71.5% | 14.7% | +2.90% | $1.95B | Benchmark Subject |
| XRAY DENTSPLY SIRONA Inc. | D | 46/100 | — | 50.0% | -11.0% | +1.80% | $1.92B | /xray-vs-lmat → |
| INSP Inspire Medical Systems Inc. | C- | 61/100 | 14.2x | 85.4% | 6.0% | +0.30% | $2.06B | /insp-vs-lmat → |
| KMTS Kestra Medical Technologies Ltd. | D- | 43/100 | — | 51.4% | -35.0% | +2.48% | $1.82B | /kmts-vs-lmat → |
| ATEC Alphatec Holdings Inc. | D- | 38/100 | — | 69.6% | -18.4% | -0.70% | $1.76B | /atec-vs-lmat → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001158895In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeMaitre Vascular Inc. (LMAT) reported GAAP revenue of $249.6M (+13.5% vs. FY2024 revenue of $219.9M , and +29.0% cumulative change since FY2023) , GAAP net income of $57.7M, operating cash flow of $81.3M, and free cash flow of $81.3M (+84.1% YoY). On the balance sheet, LMAT closed FY2025 with $615.7M in total assets against $0 in total debt (Altman Z-Score: 7.30, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $249.6M | $57.7M | $81.3M | $81.3M | $615.7M | — |
| FY2024 (FY) | 2024-12-31 | $219.9M | $44.0M | $44.1M | $44.1M | $551.8M | — |
| FY2023 (FY) | 2023-12-31 | $193.5M | $30.1M | $36.8M | $36.8M | — | — |
3. LMAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LMAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, LeMaitre Vascular Inc. (NASDAQ: LMAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $85.27 (+2.90% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, LMAT ranks #54 in composite RQD confidence.
How does LMAT compare to XRAY and INSP in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), LMAT carries a Roarable B (74/100 RQD), trailing P/E of 33.8x, gross margin of 71.5%, and ROIC of 14.7%. By comparison, XRAY (DENTSPLY SIRONA Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B) and INSP (Inspire Medical Systems Inc.) posts a C- grade (61/100 RQD, P/E 14.2x, ROIC 6.0%, cap $2.06B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LMAT?
Per LMAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001158895), LeMaitre Vascular Inc. generated $249.6M in revenue (+13.5% YoY), $57.7M in net income, and $81.3M in free cash flow against $615.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LMAT trading relative to its 50-day, 200-day, and 52-week technical levels?
LMAT last traded at $85.27 (+2.90% on volume of 300,147 shares), positioning the stock +5.01% above its 50-day simple moving average ($81.20) and -9.74% below its 200-day simple moving average ($94.47). Across its 52-week range of $78.22 to $118.01, LMAT sits at the 17.7% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($80.07 to $90.47).
LMAT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LMAT stock moving today?
Why LMAT Stock surged +2.90% Today — RQD Quant Desk Flash. High-quality cash engine (72% profit margin, 15% return on capital) with steady institutional support.